AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01666808 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FACBC
Description: FACBC is given intravenously prior to PET scan, radiotherapy decisions and treatment guided by PET findings
Study NCT03121001 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total body irradiation
Description: 3 Gy on day -1
Study NCT03121001 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stem cell infusion
Description: Stem cell product infused according to BMT unit policy on day 0.
Study NCT01666808 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiation therapy
Description: External beam radiotherapy to prostate bed +/- pelvic lymph nodes; final dose of 66.6 Gy.
Study NCT00944047 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab-paclitaxel
Description: 100 MG/M2 IV over 30 minutes once a week for 12 weeks
Study NCT00944047 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: trastuzumab
Description: 4 MG loading dose followed by 2 MG/KG every week for a total of 12 weeks
Study NCT00944047 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: 60 MG/M2 every two weeks for a total of 4 cycles
Study NCT00944047 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: 600 MG/M2 every 2 weeks for 4 cycles (administered with Doxorubicin above)
Study NCT00944047 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Growth Factor Support
Description: * All patients will receive pegfilgrastim 6.0 mg sc on Day #2 of each doxorubicin/cyclophosphamide neoadjuvant treatment cycle.~* Erythropoetic growth factor support for fatigue/anemia will be allowed at the discretion of the treating physician.
Study NCT00944047 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: * After completion of neoadjuvant therapy, patients will proceed with either modified radical mastectomy or lumpectomy.~* All patients with pretreatment lymph node positive disease and positive sentinel lymph node will undergo complete axillary lymph node dissection.
Study NCT02375295 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ciprofloxacin, cotrimoxazole-trimethoprim, macrodantin
Description: Approved antibiotics used routinely will be given at the physician's discretion with the patient: ciprofloxacin, cotrimoxazole-trimethoprim, or macrodantin
Study NCT02375295 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ciprofloxacin, cotrimoxazole-trimethoprim, macrodantin
Description: Approved antibiotics used routinely will be given at the physician's discretion with the patient: ciprofloxacin, cotrimoxazole-trimethoprim, or macrodantin
Study NCT02624544 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: esomeprazole
Description: esomex 40 mg twice daily
Study NCT02624544 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: desonide
Description: topical corticosteroid desonid 0,1% b.i.d
Study NCT03831321 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diclofenac Sodium
Description: 50 mg of diclofenac sodium will be administered to intervention group one hour before cystoscopy and lubricant gel with lidocaine will be administered to all patients just before cystoscopy.
Study NCT03831321 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cystoscopy
Description: Diagnostic cystoscopy
Study NCT03831321 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Cystoscopy
Description: Diagnostic cystoscopy
Study NCT03831321 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lubricant Gel
Description: To prevent patients from side effects of cystoscopy ( like urethral strictures and discomfort)
Study NCT03121001 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: loading dose of 15 mg followed by 5 mg per day on day +5
Study NCT03121001 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mycophenolate mofetil
Description: 1 g every 8 h (until day 35) will be started on day 5
Study NCT00955955 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 6(S)-5-MTHF(Deplin)
Description: Deplin is a medical food. Patients will take 15 mg/day of deplin.
Study NCT00955955 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Inactive substance
Study NCT03831321 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lubricant Gel
Description: To prevent patients from side effects of cystoscopy ( like urethral strictures and discomfort)
Study NCT04136886 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: cisplatin is to give from the first Day of radiation therapy D1,D22 Q3W for 2 cycles Radiation: IMRT IMRT is to give 60Gy in 27 fraction
Study NCT04136886 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: IMRT
Description: Radiation: IMRT IMRT is to give 60Gy in 27 fraction
Study NCT04136886 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: IMRT
Description: Radiation: IMRT IMRT is to give 60Gy in 27 fraction
Study NCT04612920 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen, acetaminophen, oxycodone
Description: The timing of medications is the intervention.
Study NCT02220894 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pembrolizumab
Study NCT02220894 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: carboplatin
Study NCT02220894 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: paclitaxel
Study NCT02220894 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pemetrexed
Study NCT03917368 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ultrasound scan of the internal jugular veins
Description: Participants, lying at their hospital bed, will maintain their head in a fixed position on the longitudinal axis, while an operator gently places a linear probe L12-RS (7.5-11 MHz), smeared with gel, on one side of the neck, at the middle level. A 15-sec video clip of the ultrasound images will be recorded. This procedure will be repeated on the other side of the neck. In addition, three electrodes will be placed on participants' chests and connected to the ultrasound system for simultaneously measuring the ECG signal.
Study NCT00980070 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pediatric Restraint for Lumbar Puncture
Description: Restraint for children 1-90 days of age that allows physician to position pt for optimal lumbar puncture procedure.
Study NCT00980070 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lumbar Puncture Device
Description: Lumbar Puncture positioner
Study NCT00980070 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Lumbar Puncture positioner
Study NCT02963974 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cochlear implant
Description: Implantation
Study NCT03856710 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: self-gripping mesh
Description: The initial laparoscopic approach will be the same for both groups until the process of selection and placement of the mesh (ProGripTM self-gripping mesh versus standard 'lightweight' (large pore) polypropylene mesh fixed with SecurestrapTM) which would be decided by randomization by sealed envelope into one of the 2 intervention groups: Group 1 (Self-gripping Mesh), Group 2 (Stapled Mesh).
Study NCT03856710 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Stapled mesh
Description: The initial laparoscopic approach will be the same for both groups until the process of selection and placement of the mesh (ProGripTM self-gripping mesh versus standard 'lightweight' (large pore) polypropylene mesh fixed with SecurestrapTM) which would be decided by randomization by sealed envelope into one of the 2 intervention groups: Group 1 (Self-gripping Mesh), Group 2 (Stapled Mesh).
Study NCT03868865 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Integrative mind-body-medicine group program
Description: The mind-body-medicine group program focuses on support in coping with the disease, in lifestyle modification and in reduction of chemotherapy induced side effects. The self-contained modules of the mind-body-medicine group program can be followed in an individual order, to allow adoption to different chemotherapy concepts and continued access is possible. Patients can join in the group program eleven times for six hours each visit. They participate in every one of the eleven modules once.
Study NCT03769779 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: FloraGLO Lutein
Description: Lutein (FloraGLO™) in safflower oil
Study NCT03769779 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Safflower Oil
Description: Safflower Oil
Study NCT04141527 — intervention group
Intervention type: PROCEDURE
Intervention: Spinal analgesia
Description: Spinal analgesia (SA) was provided by a resident or specialist anaesthesiologist with the patient in a sitting or a recumbent position. A pencil-point needle, primarily 27 G (0.4 mm), otherwise 25 G (0.5 mm), was used for transdermal intrathecal administration of 2.0 ml of sufentanil 5 µg/ml (Sufenta®, Janssen-Cilag AB, Solna, Sweden) at low-lumbar level. Blood pressure was recorded before, immediately after, and at five-minute intervals for 20 minutes after the block. Any decrease in systolic pressure to \<100 mmHg or a decrease >20% from the baseline level despite infusion of crystalloid was defined to indicate maternal hypotension.
Study NCT04425005 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home-based exercise
Description: Home-based exercise training, supervised by videoconference.
Study NCT02447822 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Thymoglobulin
Description: 6.0 mg/kg vs 4.5 mg/kg Thymoglobulin
Study NCT03619590 — intervention group
Intervention type: OTHER
Intervention: Data Collection
Description: When the pregnancy is reported prospectively, the Registry will collect registration data from the reporter through telephone interview or a short registration form. In the month of the estimated date of delivery, follow-up will be sought by telephone contact or a form mailed to the health professional. Information about maternal events throughout the pregnancy, pregnancy outcome, and neonatal health is requested. Additional follow-up is not sought from subsequent health care providers.
Study NCT00072761 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: transfusion therapy
Description: Those in the blood transfusion group will receive at least monthly blood transfusion therapy.
Study NCT01619202 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Risk Anticipation -Perception Training
Description: Web-based computer training program designed to teach novice teen drivers how to properly scan for hazards
Study NCT04211922 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alkotinib Capsules
Description: Alkotinib 400mg QD
Study NCT02080975 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Data Collection During Atrial Flutter Ablation
Description: All enrolled patients are clinically indicated for an atrial flutter ablation. The patients who consent for this study will have additional electrocardiograms taken during their procedure for future review, as well as ultrasound images form inside their heart. This will lengthen the ablation by approximately 10 minutes, but is not a separate procedure.
Study NCT01774864 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DA-8159 (Udenafil)
Study NCT02517190 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Parabolic flight
Study NCT02517190 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: neuro-endocrine measurements
Description: psychic stress tests, stress hormones: prolactin, cortisol, endo-cannabinoids
Study NCT02517190 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: immunological measurements
Description: blood cell counts, B2 integrins, cytokines, C-reactive protein
Study NCT02517190 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: cellular energy metabolism measurements
Description: purines, lactate
Study NCT04537676 — intervention group
Intervention type: OTHER
Intervention: No intervention, this is an observational study
Description: No intervention
Study NCT01857193 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ribociclib (LEE011)
Description: LEE011 is taken orally once per day for 21 days of each 28 day cycle. LEE011 comes in 50 mg and 200 mg capsules.
Study NCT01857193 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exemestane
Description: Exemestane is taken orally once per day. Exemestane comes in 25 mg tablets.
Study NCT01857193 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus (RAD001)
Description: Everolimus is taken orally once per day. Everolimus comes in 1 mg, 2.5 mg, 5mg, and 7.5 mg tablets
Study NCT02406833 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TGF-β2 antisense oligonucleotide
Description: intravitreal injection
Study NCT02406833 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Trabeculectomy
Description: Standard trabeculectomy with the use of antimetabolites (mitomycin C) for glaucoma patients with insufficient intraocular pressure (IOP) control
Study NCT01774864 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00538590 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Collagen Matrix in Glaucoma Filtering Surgery
Description: Collagen Matrix implantation in Glaucoma Filtering Surgery
Study NCT00538590 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mitomycin-C(MMC) and glaucoma filtering surgery
Description: If mitomycin -C is applied, a single cellulose sponge soaked with Mitomycin-C(MMC) (0.2mg/ml - 0.4mg/ml) is fashioned into an approximate 2.0 × 4.0 mm rectangular shape and applied to the scleral bed and subconjunctival space taking care to avoid exposure to the conjunctival wound edge. Application time is 2 minutes for MMC. Then, the area treated is copiously irrigated with balanced salt solution. After operation, appropriate anti-inflammatory and antibiotic eye-drops will be prescribed.
Study NCT04059666 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Investigational
Description: Cow's milk-based Infant Formula with whey protein-lipid concentrate
Study NCT04059666 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Cow's milk-based Infant Formula
Study NCT04634110 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brigatinib
Description: At day 1, all patients will be started on brigatinib 90 mg daily for 7 days, before escalating to 180 mg daily thereafter as tolerated.
Study NCT01338428 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced AAA Sexual Assault Resistance Education
Description: Resistance Program: 4x3-hour units. Unit 1 (Assess) accurate assessment of sexual assault risk. Provides: empirically-based information on situational and (male) behavioural danger cues; practice identifying risk and counteracting it. Unit 2 'Acknowledge\[ment\]' of risk when present. Includes: women's sexual rights; emotional barriers; tactics used by coercive men; practice. Unit 3 (Act) includes: assessing whether or not an escape is possible; research evidence on the effectiveness of resistance strategies; physical self-defense training. Unit 4 applies content to longer term relationships covering: comfort talking about sexuality, identification of sexual values, practices beyond intercourse, and articulation of relationship goals.
Study NCT01338428 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Brochure
Description: Current 'standard of care' at Canadian universities. Invitation to take and read brochures on sexual assault selected from those available on their Canadian university campus. All sites' brochures include general information on sexual assault and 'date-rape' drugs and post-rape legal and medical advice. The research assistant (RA) will ask the participants to take brochures, read them over, and to ask any questions they may have. Questions will be answered in a group setting and the participant will take home any brochures that she selected. Interaction between participants and the RA on the topic will be limited to 10-15 minutes and will be audio recorded for verification.
Study NCT00994838 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: reduced calorie diet
Description: 10% reduction in total daily calories (≈ 300 kcal reduction) from carbohydrates and fat from the usual daily energy consumption
Study NCT02563496 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tafenoquine
Description: Tafenoquine tablet is supplied as film-coated tablet (100 mg, 150 mg, 200 mg and 300 mg) and fast-dispersing film coated tablet (50 mg).
Study NCT03805828 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Educational program on parenting stress and coping mechanism
Description: The educational program will deliver as a one-day event in four sessions: (1)background of autism spectrum disorder(ASD) and coping mechanism,(2) targeting communication and social difficulties among ASD children using coping mechanism,(3) targeting behavior problems among ASD children using coping mechanism, and (4) stress management as coping mechanism. The contents of the educational program deliver through the use of PowerPoint slides, Whiteboard and marker, practical exercise, video clips followed by group discussion and provision a hard copy booklet containing all items which were supposed to discuss. As well as each session will approximately be taken one hour. Each group will consist of 10 participants.
Study NCT03805828 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational program on parenting stress and coping mechanism
Description: The educational program will deliver as a one-day event in four sessions: (1)background of autism spectrum disorder(ASD) and coping mechanism,(2) targeting communication and social difficulties among ASD children using coping mechanism,(3) targeting behavior problems among ASD children using coping mechanism, and (4) stress management as coping mechanism. The contents of the educational program deliver through the use of PowerPoint slides, Whiteboard and marker, practical exercise, video clips followed by group discussion and provision a hard copy booklet containing all items which were supposed to discuss. As well as each session will approximately be taken one hour. Each group will consist of 10 participants.
Study NCT00908752 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Brivanib
Description: Tablets, Oral, 200 mg, once daily, until disease progression or toxicity
Study NCT00908752 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Brivanib Placebo
Description: Tablets, Oral, 0 mg, once daily, until disease progression or toxicity
Study NCT00908752 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TACE Therapy
Description: Trans-Arterial Chemo-Embolization Therapy
Study NCT00908752 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: TACE Therapy
Description: Trans-Arterial Chemo-Embolization Therapy
Study NCT01693484 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ICG (Indocyanine Green)
Description: Diagnostic drug used for visualisation of blood perfusion in various tissues.Administered intravenously, 2X: 1X prior to anesthesia, and 1X after tourniquet on operative extremity has been released for at least 15 minutes. When excited by laser light source, it subsequently emits at a near infrared frequency.
Study NCT02849925 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sealants to arrest microcavitated caries.
Description: Carious lesions will be treated by minimally invasive dentistry by the use of sealants instead of eliminating carious tissues and using conventional restorative materials.
Study NCT02849925 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sealants to arrest microcavitated caries.
Description: Carious lesions will be treated by minimally invasive dentistry by the use of sealants instead of eliminating carious tissues and using conventional restorative materials.
Study NCT02563496 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chloroquine
Description: Subjects may receive chloroquine according to local/national treatment guidelines.
Study NCT03150979 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Provision of a cane
Description: The participants will receive a single-point cane and will be instructed to use it all the time during locomotion. Weekly, they will receive a phone call, to ensure that they are using the cane and to clarify any doubts. A home visit may be conducted, if necessary.
Study NCT03150979 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Control
Description: The control group will be instructed to to perform stretching of the lower limb muscles daily and keep their daily activities, without the use of a cane. They will also receive weekly phone calls, to ensure similar level of attention to that of the the participants in the experimental group.
Study NCT01760122 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ypeginterferon alfa-2b
Description: sc, qw, 48 weeks.
Study NCT01947465 — intervention group
Intervention type: BIOLOGICAL
Intervention: Hepatitis A vaccine and tetanus vaccine
Description: Hepatitis A and/or tetanus vaccination will be given to participants in all group on day 0. All monovalent active hepatitis A vaccinations and all vaccines containing tetanus toxoid available in Switzerland may be used in the study
Study NCT01760122 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pegasys
Description: sc, qw, 48 weeks.